TVGN vs. ALGS, INAB, NKGN, OKYO, ACHL, CYTH, QNCX, SRZN, ESLA, and BCLI
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Aligos Therapeutics (ALGS), IN8bio (INAB), NKGen Biotech (NKGN), OKYO Pharma (OKYO), Achilles Therapeutics (ACHL), Cyclo Therapeutics (CYTH), Quince Therapeutics (QNCX), Surrozen (SRZN), Estrella Immunopharma (ESLA), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "biological products, except diagnostic" industry.
Tevogen Bio (NASDAQ:TVGN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.
Tevogen Bio has higher earnings, but lower revenue than Aligos Therapeutics.
Tevogen Bio has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -783.72%. Aligos Therapeutics' return on equity of -144.16% beat Tevogen Bio's return on equity.
60.4% of Aligos Therapeutics shares are held by institutional investors. 56.6% of Tevogen Bio shares are held by company insiders. Comparatively, 16.5% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aligos Therapeutics received 23 more outperform votes than Tevogen Bio when rated by MarketBeat users.
Tevogen Bio has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
In the previous week, Tevogen Bio had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Tevogen Bio and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.66 beat Tevogen Bio's score of 0.47 indicating that Aligos Therapeutics is being referred to more favorably in the news media.
Summary
Aligos Therapeutics beats Tevogen Bio on 6 of the 11 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
